Amin Li

613 total citations
25 papers, 428 citations indexed

About

Amin Li is a scholar working on Molecular Biology, Hepatology and Pathology and Forensic Medicine. According to data from OpenAlex, Amin Li has authored 25 papers receiving a total of 428 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 8 papers in Hepatology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Amin Li's work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Cancer Mechanisms and Therapy (4 papers). Amin Li is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (6 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Cancer Mechanisms and Therapy (4 papers). Amin Li collaborates with scholars based in China and United States. Amin Li's co-authors include Yinci Zhang, Xinkuang Liu, Ruyue Xu, Xueke Liu, Yongfang Ma, Weiya Cao, Yong Liang, Shuping Zhou, Xiaolong Tang and Shuyu Cai and has published in prestigious journals such as PLoS ONE, Cancer Research and BioMed Research International.

In The Last Decade

Amin Li

22 papers receiving 423 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amin Li China 15 233 101 88 84 80 25 428
Yinci Zhang China 15 252 1.1× 92 0.9× 84 1.0× 67 0.8× 98 1.2× 23 458
Xinkuang Liu China 11 190 0.8× 64 0.6× 57 0.6× 70 0.8× 80 1.0× 12 349
Yantao Chai China 11 276 1.2× 90 0.9× 160 1.8× 34 0.4× 207 2.6× 19 551
Allen Zhang United States 10 397 1.7× 40 0.4× 133 1.5× 77 0.9× 141 1.8× 16 565
Qian Qiao China 12 239 1.0× 30 0.3× 66 0.8× 45 0.5× 53 0.7× 25 439
Jiafeng Gao China 15 250 1.1× 39 0.4× 79 0.9× 41 0.5× 101 1.3× 22 472
Dar-Shih Hsieh Taiwan 13 187 0.8× 93 0.9× 100 1.1× 38 0.5× 71 0.9× 23 501
Qie Guo China 13 209 0.9× 66 0.7× 100 1.1× 89 1.1× 77 1.0× 41 497
Prameswari Kasa India 7 231 1.0× 23 0.2× 55 0.6× 81 1.0× 96 1.2× 7 403
Xuefeng Liu China 11 265 1.1× 30 0.3× 115 1.3× 36 0.4× 195 2.4× 21 528

Countries citing papers authored by Amin Li

Since Specialization
Citations

This map shows the geographic impact of Amin Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amin Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amin Li more than expected).

Fields of papers citing papers by Amin Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amin Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amin Li. The network helps show where Amin Li may publish in the future.

Co-authorship network of co-authors of Amin Li

This figure shows the co-authorship network connecting the top 25 collaborators of Amin Li. A scholar is included among the top collaborators of Amin Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amin Li. Amin Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Li, Amin, et al.. (2024). Nano-encapsulation of EGCG in dextran 70-stabilized chitosan/SDS nanoparticles: Characterization, permeability behavior and oral bioavailability. European Polymer Journal. 205. 112763–112763. 5 indexed citations
3.
Wang, Peng, Liang Chen, Amin Li, et al.. (2024). Abstract 5940: JAB-30355: A highly potent, orally bioavailable p53-Y220C reactivator. Cancer Research. 84(6_Supplement). 5940–5940. 1 indexed citations
4.
Wang, Peng George, Yanping Wang, Dan Liu, et al.. (2023). Abstract 1660: Preclinical investigation of orally bioavailable, potent KRASMulti inhibitor JAB-23425. Cancer Research. 83(7_Supplement). 1660–1660. 3 indexed citations
5.
Zhang, Yinci, et al.. (2022). A pan-cancer analysis on the carcinogenic effect of human adenomatous polyposis coli. PLoS ONE. 17(3). e0265655–e0265655. 13 indexed citations
6.
Xu, Ruyue, Xinkuang Liu, Amin Li, et al.. (2022). c-Met up-regulates the expression of PD-L1 through MAPK/NF-κBp65 pathway. Journal of Molecular Medicine. 100(4). 585–598. 25 indexed citations
7.
Cao, Weiya, Xueke Liu, Amin Li, et al.. (2021). BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy. BioMed Research International. 2021(1). 5556306–5556306. 18 indexed citations
8.
Liu, Changwei, et al.. (2021). PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair. PLoS ONE. 16(10). e0258817–e0258817. 19 indexed citations
9.
Cao, Weiya, Yinci Zhang, Amin Li, et al.. (2021). Curcumin reverses hepatic epithelial mesenchymal transition induced by trichloroethylene by inhibiting IL-6R/STAT3. Toxicology Mechanisms and Methods. 31(8). 589–599. 19 indexed citations
10.
Xu, Ruyue, Yinci Zhang, Amin Li, et al.. (2021). LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway. Molecular Medicine Reports. 24(1). 22 indexed citations
11.
Ma, Yongfang, Ruyue Xu, Xueke Liu, et al.. (2021). LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells. International Journal of Medical Sciences. 18(6). 1456–1464. 28 indexed citations
12.
Li, Amin, Weiya Cao, Xueke Liu, et al.. (2020). Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells. Journal of Cancer Research and Clinical Oncology. 146(7). 1737–1749. 14 indexed citations
13.
Shen, Jing, Yongfang Ma, Ruyue Xu, et al.. (2020). hGC33-Modified and Sorafenib-Loaded Nanoparticles have a Synergistic Anti-Hepatoma Effect by Inhibiting Wnt Signaling Pathway. Nanoscale Research Letters. 15(1). 220–220. 17 indexed citations
14.
Li, Amin, Weiya Cao, Xueke Liu, et al.. (2020). Increased efficacy of gefitinib on cisplatin-resistant wild-type epidermal growth factor receptor non-small cell lung cancer cells. Translational Cancer Research. 9(9). 5473–5483. 1 indexed citations
15.
Zhang, Yinci, Chunmei Xie, Amin Li, et al.. (2019). PKI-587 enhances chemosensitivity of oxaliplatin in hepatocellular carcinoma through suppressing DNA damage repair pathway (NHEJ and HR) and PI3K/AKT/mTOR pathway.. PubMed. 11(8). 5134–5149. 36 indexed citations
16.
Li, Amin, Rongbo Zhang, Yinci Zhang, et al.. (2019). BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway.. PubMed. 11(9). 5573–5585. 29 indexed citations
17.
Li, Amin, Yinci Zhang, Xueke Liu, et al.. (2018). Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma. Materials Science and Engineering C. 91. 395–403. 45 indexed citations
18.
Tang, Xiaolong, Amin Li, Yinci Zhang, et al.. (2018). Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. Drug Delivery. 25(1). 1484–1494. 55 indexed citations
19.
Wang, Xiaowei, Yanli Chen, Ying Guo, et al.. (2007). Synthesis of 1‐(Alkyl)‐5‐dimethylamino‐6‐phenethyluracils as Potent Nonnucleoside HIV‐1 RT Inhibitors. Synthetic Communications. 37(14). 2421–2431. 5 indexed citations
20.
Akey, Dayna T., Xuemei Zhu, Michael A. Dyer, et al.. (2003). Functional Studies of AIPL1. Advances in experimental medicine and biology. 533. 287–295.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yinci Zhang Breakdown of academic impact, for papers by Xinkuang Liu Breakdown of academic impact, for papers by Yantao Chai Breakdown of academic impact, for papers by Allen Zhang Breakdown of academic impact, for papers by Qian Qiao Breakdown of academic impact, for papers by Jiafeng Gao Breakdown of academic impact, for papers by Dar-Shih Hsieh Breakdown of academic impact, for papers by Qie Guo Breakdown of academic impact, for papers by Prameswari Kasa Breakdown of academic impact, for papers by Xuefeng Liu
Rankless by CCL
2026